• In the last decade, many new therapies (e.g. thalidomide, bortezomib, lenalidomide, pomalidomide) have become available for the treatment of relapsed and/or refractory multiple myeloma (RRMM) and significantly improved response rates and survival outcomes. More novel agents are coming to the market or are in development (e.g. carfilzomib, panobinostat, elotuzumab, daratumumab).
• To inform and improve economic evaluations of new therapies for RRMM, it is important to learn from approaches used in the past drug submissions, as well as feedback from the health technology assessments (HTA) agencies.
• To identify and summarize previous HTA submissions in RRMM, and use pCODR and NICE's critiques to formulate recommendations for future economic evaluations.
• It is interesting to note that pomalidomide received a positive recommendation in Canada but not in the UK. This may be due to differences in the decision framework used by the two HTA agencies.
 In the UK, currently NICE uses a threshold of £20,000-30,000 per quality-adjusted life year (QALY) gained. 5  In Canada, there is no explicit cost-effectiveness threshold and recommendations are made based on a deliberative framework which included overall clinical benefit, alignment with patient values, costeffectiveness, and feasibility of adoption. 6 Pricing negotiation is undertaken by individual drug plans, or the pan-Canadian Pricing Alliance (pCPA).
• A targeted search of the pCODR and NICE websites was performed to identify previous RRMM economic evaluations since 2007.
• Details of the modelling methods were extracted, including model structure, comparators, data sources for clinical effectiveness, survival extrapolation approach, time horizon, and model assumptions. Critiques from pCODR and NICE were also extracted.
• The findings of this study suggest that most problems identified by pCODR and NICE could be avoided if the submissions conform to the method guidance set by the reimbursement authorities.
• It is helpful to include patient access schemes in the model for HTA agencies to explore.
Results/Discussion
• Four submissions in RRMM were identified. 1, 2, 3, 4 The drugs evaluated included lenalidomide, bortezomib, and pomalidomide. (Table 1) • Model structures used included partitioned survival model, semi-Markov model, and discrete-event stimulation model, all of which are considered appropriate. All models used a lifetime horizon, which varied from 10 to 30 years.
• Since crossover was allowed in the key clinical trials used to inform the clinical effectiveness, external data were used to adjust the survival estimates in all four economic evaluations.
• Main issues criticized by pCODR and NICE were inappropriate comparators, bias against comparators (e.g. underestimating survival, overestimating costs), bias favouring the drug of interest (e.g. not including costs and disutility of adverse events), and validity of health state utility values. (Table 1) • Three of the evaluations received a positive recommendation, despite of high incremental costeffectiveness ratios.
 Risk sharing agreements were used in the UK. For lenalidomide, manufacturer agreed to cover the drug cost for people who remain on treatment for more than 26 cycles (normally 2 years). 3 For bortezomib, manufacturer rebated the drug cost for people who have less than a partial response after 4 cycles. 4  There may be product listing agreement in Canada for pomalidomide. However, such information is not publically available. 
Comparators
• BSC (a combination of therapies weighted by average usage)
• Bortezomib/HDex • 
